Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Phase 1 clinical trials

J J Muglia1, J J DiGiovanna

  • 1Dermatopharmacology Division, Department of Dermatology, Brown University School of Medicine, Providence, Rhode Island, USA.

Journal of Cutaneous Medicine and Surgery
|May 19, 1998
PubMed
Summary

Phase 1 clinical trials focus on early safety and pharmacology of new drugs in limited human exposure. While preliminary efficacy may be observed, robust evaluation requires larger, controlled studies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Thyroid nodules in xeroderma pigmentosum patients: a feature of premature aging.

Journal of endocrinological investigation·2020
Same author

Molecular diagnosis of xeroderma pigmentosum variant in an isolated population: the interface between precision medicine and public health.

The British journal of dermatology·2017
Same author

Activated STING in a vascular and pulmonary syndrome.

The New England journal of medicine·2014
Same author

Burning issues in the diagnosis of xeroderma pigmentosum.

The British journal of dermatology·2013
Same author

Adverse effects of trichothiodystrophy DNA repair and transcription gene disorder on human fetal development.

Clinical genetics·2009
Same author

Trichothiodystrophy: a systematic review of 112 published cases characterises a wide spectrum of clinical manifestations.

Journal of medical genetics·2008

Area of Science:

  • Pharmacology
  • Clinical Trials
  • Drug Development

Background:

  • The U.S. Food and Drug Administration (FDA) regulates drug approval through a multi-step process.
  • Early human exposure to new drugs occurs in a graded manner to minimize participant risk.
  • Phase 1 trials provide initial data on pharmacology, short-term toxicity, and potential efficacy.

Purpose of the Study:

  • To review the drug approval process, emphasizing Phase 1 trials.
  • To describe the purpose, variations, and significance of Phase 1 trials.
  • To offer a framework for critically evaluating Phase 1 trial data.

Main Methods:

  • Review of the drug approval process and Phase 1 trial design.
  • Analysis of data collection and interpretation in early-stage drug development.
  • Framework development for critical appraisal of Phase 1 trial outcomes.

Main Results:

  • Phase 1 trials prioritize short-term safety (toxicity) and pharmacological data.
  • Preliminary efficacy (proof of concept) is a secondary endpoint in Phase 1.
  • Small patient numbers and lack of controls limit definitive efficacy conclusions.

Conclusions:

  • Phase 1 trials are crucial for initial safety and pharmacology assessment.
  • Efficacy and long-term toxicity require larger, controlled studies.
  • Critical evaluation of Phase 1 data necessitates understanding its inherent limitations.

Related Experiment Videos